Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd PharmaphorumBoehringer Ingelheim has won the first European approval for its new idiopathic pulmonary fibrosis (IPF) therapy, Jascayd, in the UK.RespiratoryRead full story pharminent July 9, 2026 (Last updated: July 9, 2026) Pharmaphorum Boehringer Ingelheim has won the first European approval for its new idiopathic pulmonary fibrosis (IPF) therapy, Jascayd, in the UK. Respiratory Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA Warning Letter Hits Sanofi’s Genzyme Ireland SiteNext: NICE aims to cut funding for Amgen lung cancer drug Lumykras Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
